Physician profile
Stephen Havens
NPI 1982667291
$1,586.78
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $746 · 2021: $38.64 · 2022: $16.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $459.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $235.82 | 2019-2020 | |
| Amgen INC. | $199.25 | 2019-2020 | |
| Pfizer INC. | $111.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $103.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $98.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $76.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.20 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.95 | 2019 | |
| Abbvie INC. | $55.05 | 2021-2022 | |
| Amarin Pharma, INC. | $42.31 | 2019-2020 | |
| Astellas Pharma US INC | $34.06 | 2019-2020 | |
| Mylan Specialty L.P. | $24.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $13.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Havens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.